Literature DB >> 25623732

Population distribution of lifetime risk of ovarian cancer in the United States.

Malcolm C Pike1,2, Paul D P Pharoah3,4, Celeste Leigh Pearce5,1, Daniel O Stram1, Roberta B Ness6, Douglas A Stram1, Lynda D Roman7, Claire Templeman7, Alice W Lee1, Usha Menon8, Peter A Fasching9,10, Jessica N McAlpine11, Jennifer A Doherty12, Francesmary Modugno13,14,15, Joellen M Schildkraut16,17, Mary Anne Rossing18,19, David G Huntsman20, Anna H Wu1, Andrew Berchuck21.   

Abstract

BACKGROUND: In U.S. women, lifetime risk of ovarian cancer is 1.37%, but some women are at a substantially lower or higher risk than this average.
METHODS: We have characterized the distribution of lifetime risk in the general population. Published data on the relative risks and their variances for five well-accepted risk and protective factors for ovarian cancer, oral contraceptive use, parity, tubal ligation, endometriosis, and first-degree family history of ovarian cancer in conjunction with a genetic risk score using genome-wide significant common, low penetrance variants were used. The joint distribution of these factors (i.e., risk/protective factor profiles) was derived using control data from four U.S. population-based studies, providing a broad representation of women in the United States.
RESULTS: A total of 214 combinations of risk/protective factors were observed, and the lifetime risk estimates ranged from 0.35% [95% confidence interval (CI), 0.29-0.42] to 8.78% (95% CI, 7.10-10.9). Among women with lifetime risk ranging from 4% to 9%, 73% had no family history of ovarian cancer; most of these women had a self-reported history of endometriosis.
CONCLUSIONS: Profiles including the known modifiable protective factors of oral contraceptive use and tubal ligation were associated with a lower lifetime risk of ovarian cancer. Oral contraceptive use and tubal ligation were essentially absent among the women at 4% to 9% lifetime risk. IMPACT: This work demonstrates that there are women in the general population who have a much higher than average lifetime risk of ovarian cancer. Preventive strategies are available. Should effective screening become available, higher than average risk women can be identified. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25623732      PMCID: PMC4892114          DOI: 10.1158/1055-9965.EPI-14-1128

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  20 in total

Review 1.  The distal fallopian tube: a new model for pelvic serous carcinogenesis.

Authors:  Christopher P Crum; Ronny Drapkin; Alexander Miron; Tan A Ince; Michael Muto; David W Kindelberger; Yonghee Lee
Journal:  Curr Opin Obstet Gynecol       Date:  2007-02       Impact factor: 1.927

2.  Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention.

Authors:  Jessica N McAlpine; Gillian E Hanley; Michelle M M Woo; Alicia A Tone; Nirit Rozenberg; Kenneth D Swenerton; C Blake Gilks; Sarah J Finlayson; David G Huntsman; Dianne M Miller
Journal:  Am J Obstet Gynecol       Date:  2014-01-09       Impact factor: 8.661

3.  Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.

Authors:  Janice S Kwon; Anna Tinker; Gary Pansegrau; Jessica McAlpine; Melissa Housty; Mary McCullum; C Blake Gilks
Journal:  Obstet Gynecol       Date:  2013-01       Impact factor: 7.661

4.  A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.

Authors:  Ellen L Goode; Georgia Chenevix-Trench; Honglin Song; Susan J Ramus; Maria Notaridou; Kate Lawrenson; Martin Widschwendter; Robert A Vierkant; Melissa C Larson; Susanne K Kjaer; Michael J Birrer; Andrew Berchuck; Joellen Schildkraut; Ian Tomlinson; Lambertus A Kiemeney; Linda S Cook; Jacek Gronwald; Montserrat Garcia-Closas; Martin E Gore; Ian Campbell; Alice S Whittemore; Rebecca Sutphen; Catherine Phelan; Hoda Anton-Culver; Celeste Leigh Pearce; Diether Lambrechts; Mary Anne Rossing; Jenny Chang-Claude; Kirsten B Moysich; Marc T Goodman; Thilo Dörk; Heli Nevanlinna; Roberta B Ness; Thorunn Rafnar; Claus Hogdall; Estrid Hogdall; Brooke L Fridley; Julie M Cunningham; Weiva Sieh; Valerie McGuire; Andrew K Godwin; Daniel W Cramer; Dena Hernandez; Douglas Levine; Karen Lu; Edwin S Iversen; Rachel T Palmieri; Richard Houlston; Anne M van Altena; Katja K H Aben; Leon F A G Massuger; Angela Brooks-Wilson; Linda E Kelemen; Nhu D Le; Anna Jakubowska; Jan Lubinski; Krzysztof Medrek; Anne Stafford; Douglas F Easton; Jonathan Tyrer; Kelly L Bolton; Patricia Harrington; Diana Eccles; Ann Chen; Ashley N Molina; Barbara N Davila; Hector Arango; Ya-Yu Tsai; Zhihua Chen; Harvey A Risch; John McLaughlin; Steven A Narod; Argyrios Ziogas; Wendy Brewster; Aleksandra Gentry-Maharaj; Usha Menon; Anna H Wu; Daniel O Stram; Malcolm C Pike; Jonathan Beesley; Penelope M Webb; Xiaoqing Chen; Arif B Ekici; Falk C Thiel; Matthias W Beckmann; Hannah Yang; Nicolas Wentzensen; Jolanta Lissowska; Peter A Fasching; Evelyn Despierre; Frederic Amant; Ignace Vergote; Jennifer Doherty; Rebecca Hein; Shan Wang-Gohrke; Galina Lurie; Michael E Carney; Pamela J Thompson; Ingo Runnebaum; Peter Hillemanns; Matthias Dürst; Natalia Antonenkova; Natalia Bogdanova; Arto Leminen; Ralf Butzow; Tuomas Heikkinen; Kari Stefansson; Patrick Sulem; Sören Besenbacher; Thomas A Sellers; Simon A Gayther; Paul D P Pharoah
Journal:  Nat Genet       Date:  2010-09-19       Impact factor: 38.330

5.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Authors:  Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs
Journal:  Lancet Oncol       Date:  2009-03-11       Impact factor: 41.316

6.  Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.

Authors:  V Beral; R Doll; C Hermon; R Peto; G Reeves
Journal:  Lancet       Date:  2008-01-26       Impact factor: 79.321

7.  Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study.

Authors:  Malcolm C Pike; Celeste L Pearce; Ruth Peters; Wendy Cozen; Peggy Wan; Anna H Wu
Journal:  Fertil Steril       Date:  2004-07       Impact factor: 7.329

8.  Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies.

Authors:  Weiva Sieh; Shannon Salvador; Valerie McGuire; Rachel Palmieri Weber; Kathryn L Terry; Mary Anne Rossing; Harvey Risch; Anna H Wu; Penelope M Webb; Kirsten Moysich; Jennifer A Doherty; Anna Felberg; Dianne Miller; Susan J Jordan; Marc T Goodman; Galina Lurie; Jenny Chang-Claude; Anja Rudolph; Susanne Krüger Kjær; Allan Jensen; Estrid Høgdall; Elisa V Bandera; Sara H Olson; Melony G King; Lorna Rodriguez-Rodriguez; Lambertus A Kiemeney; Tamara Marees; Leon F Massuger; Anne M van Altena; Roberta B Ness; Daniel W Cramer; Malcolm C Pike; Celeste Leigh Pearce; Andrew Berchuck; Joellen M Schildkraut; Alice S Whittemore
Journal:  Int J Epidemiol       Date:  2013-04       Impact factor: 7.196

9.  Common variants at 19p13 are associated with susceptibility to ovarian cancer.

Authors:  Kelly L Bolton; Jonathan Tyrer; Honglin Song; Susan J Ramus; Maria Notaridou; Chris Jones; Tanya Sher; Aleksandra Gentry-Maharaj; Eva Wozniak; Ya-Yu Tsai; Joanne Weidhaas; Daniel Paik; David J Van Den Berg; Daniel O Stram; Celeste Leigh Pearce; Anna H Wu; Wendy Brewster; Hoda Anton-Culver; Argyrios Ziogas; Steven A Narod; Douglas A Levine; Stanley B Kaye; Robert Brown; Jim Paul; James Flanagan; Weiva Sieh; Valerie McGuire; Alice S Whittemore; Ian Campbell; Martin E Gore; Jolanta Lissowska; Hanna P Yang; Krzysztof Medrek; Jacek Gronwald; Jan Lubinski; Anna Jakubowska; Nhu D Le; Linda S Cook; Linda E Kelemen; Angela Brooks-Wilson; Angela Brook-Wilson; Leon F A G Massuger; Lambertus A Kiemeney; Katja K H Aben; Anne M van Altena; Richard Houlston; Ian Tomlinson; Rachel T Palmieri; Patricia G Moorman; Joellen Schildkraut; Edwin S Iversen; Catherine Phelan; Robert A Vierkant; Julie M Cunningham; Ellen L Goode; Brooke L Fridley; Susan Kruger-Kjaer; Jan Blaeker; Estrid Hogdall; Claus Hogdall; Jenny Gross; Beth Y Karlan; Roberta B Ness; Robert P Edwards; Kunle Odunsi; Kirsten B Moyisch; Julie A Baker; Francesmary Modugno; Tuomas Heikkinenen; Ralf Butzow; Heli Nevanlinna; Arto Leminen; Natalia Bogdanova; Natalia Antonenkova; Thilo Doerk; Peter Hillemanns; Matthias Dürst; Ingo Runnebaum; Pamela J Thompson; Michael E Carney; Marc T Goodman; Galina Lurie; Shan Wang-Gohrke; Rebecca Hein; Jenny Chang-Claude; Mary Anne Rossing; Kara L Cushing-Haugen; Jennifer Doherty; Chu Chen; Thorunn Rafnar; Soren Besenbacher; Patrick Sulem; Kari Stefansson; Michael J Birrer; Kathryn L Terry; Dena Hernandez; Daniel W Cramer; Ignace Vergote; Frederic Amant; Diether Lambrechts; Evelyn Despierre; Peter A Fasching; Matthias W Beckmann; Falk C Thiel; Arif B Ekici; Xiaoqing Chen; Sharon E Johnatty; Penelope M Webb; Jonathan Beesley; Stephen Chanock; Montserrat Garcia-Closas; Tom Sellers; Douglas F Easton; Andrew Berchuck; Georgia Chenevix-Trench; Paul D P Pharoah; Simon A Gayther
Journal:  Nat Genet       Date:  2010-09-19       Impact factor: 41.307

10.  Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer.

Authors:  Celeste Leigh Pearce; Mary Anne Rossing; Alice W Lee; Roberta B Ness; Penelope M Webb; Georgia Chenevix-Trench; Susan M Jordan; Douglas A Stram; Jenny Chang-Claude; Rebecca Hein; Stefan Nickels; Galina Lurie; Pamela J Thompson; Michael E Carney; Marc T Goodman; Kirsten Moysich; Estrid Hogdall; Allan Jensen; Ellen L Goode; Brooke L Fridley; Julie M Cunningham; Robert A Vierkant; Rachel Palmieri Weber; Argyrios Ziogas; Hoda Anton-Culver; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; Susan J Ramus; Louise Brinton; Nicolas Wentzensen; Jolanta Lissowska; Montserrat Garcia-Closas; Leon F A G Massuger; Lambertus A L M Kiemeney; Anne M Van Altena; Katja K H Aben; Andrew Berchuck; Jennifer A Doherty; Edwin Iversen; Valerie McGuire; Patricia G Moorman; Paul Pharoah; Malcolm C Pike; Harvey Risch; Weiva Sieh; Daniel O Stram; Kathryn L Terry; Alice Whittemore; Anna H Wu; Joellen M Schildkraut; Susanne K Kjaer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-05       Impact factor: 4.254

View more
  34 in total

Review 1.  A Management Protocol for Gonad Preservation in Patients with Androgen Insensitivity Syndrome.

Authors:  Erica M Weidler; Maria E Linnaus; Arlene B Baratz; Luis F Goncalves; Smita Bailey; S Janett Hernandez; Veronica Gomez-Lobo; Kathleen van Leeuwen
Journal:  J Pediatr Adolesc Gynecol       Date:  2019-06-21       Impact factor: 1.814

Review 2.  Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.

Authors:  Anthony N Karnezis; Kathleen R Cho
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

Review 3.  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Authors:  Mark E Sherman; Ronny I Drapkin; Neil S Horowitz; Christopher P Crum; Sue Friedman; Janice S Kwon; Douglas A Levine; Ie-Ming Shih; Donna Shoupe; Elizabeth M Swisher; Joan Walker; Britton Trabert; Mark H Greene; Goli Samimi; Sarah M Temkin; Lori M Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-24

Review 4.  The disparate origins of ovarian cancers: pathogenesis and prevention strategies.

Authors:  Anthony N Karnezis; Kathleen R Cho; C Blake Gilks; Celeste Leigh Pearce; David G Huntsman
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

5.  Tubal ligation and ovarian cancer risk in African American women.

Authors:  Chrissy McNamara; Sarah E Abbott; Elisa V Bandera; Bo Qin; Lauren C Peres; Fabian Camacho; Patricia G Moorman; Anthony J Alberg; Jill S Barnholtz-Sloan; Melissa Bondy; Michele L Cote; Ellen Funkhouser; Edward S Peters; Ann G Schwartz; Joellen M Schildkraut; Paul Terry
Journal:  Cancer Causes Control       Date:  2017-09-04       Impact factor: 2.506

Review 6.  Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.

Authors:  Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2017-10-01       Impact factor: 13.506

7.  Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.

Authors:  Paul F Pinsky; Kelly Yu; Barnett S Kramer; Amanda Black; Saundra S Buys; Edward Partridge; John Gohagan; Christine D Berg; Philip C Prorok
Journal:  Gynecol Oncol       Date:  2016-09-09       Impact factor: 5.482

8.  Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.

Authors:  Yi Yu-Rice; Seby L Edassery; Nicole Urban; Ingegerd Hellstrom; Karl Erik Hellstrom; Youping Deng; Yan Li; Judith L Luborsky
Journal:  Reproduction       Date:  2016-12-13       Impact factor: 3.906

9.  Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.

Authors:  Nicole Urban; Sarah Hawley; Holly Janes; Beth Y Karlan; Christine D Berg; Charles W Drescher; JoAnn E Manson; Melanie R Palomares; Mary B Daly; Jean Wactawski-Wende; Mary J O'Sullivan; Jason Thorpe; Randal D Robinson; Dorothy Lane; Christopher I Li; Garnet L Anderson
Journal:  Gynecol Oncol       Date:  2015-09-03       Impact factor: 5.482

Review 10.  Hysteropexy: an Option for the Repair of Pelvic Organ Prolapse.

Authors:  Sarah Bradley; Robert E Gutman; Lee A Richter
Journal:  Curr Urol Rep       Date:  2018-02-23       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.